COLUMBUS, Ohio–(BUSINESS WIRE)–Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapeutic for ischemic stroke, today presented positive results of a Phase 1 single ascending dose safety study in healthy volunteers of the company’s novel von Willebrand Factor (vWF)-targeting thrombolytic agent, BB-031. BB-031 demonstrated safety and tolerability following a single intravenous dose ranging from 0.1 mg/kg to 4.0 mg/kg and dose-dependent patterns of vWF binding and changes in platelet function. Two oral presentations and two moderated posters concerning BB-031 were presented at the American Heart Association International Stroke Conference (ISC) 2023 being held in Dallas, Texas from February 8 – 10.